Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

Real-time Quote. Real-time Tradegate - 02/10 05:50:06 am
36.893 EUR   +3.52%
01/29 MORPHOSYS : Announces Clinical Milestone for Start of Bayer's Phase ..
01/28 MORPHOSYS : Announces Clinical Milestone for Start of Bayer's Phase ..
01/26 MORPHOSYS : Announces Clinical Milestone for Start of Bayer's Phase ..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Xetra
02/03/2016 02/04/2016 02/05/2016 02/08/2016 02/09/2016 Date
41.795(c) 42.485(c) 41.685(c) 38.285(c) 35.64(c) Last
138 799 102 580 126 794 193 762 276 672 Volume
-2.43% +1.65% -1.88% -8.16% -6.91% Change
More quotes
Financials (€)
Sales 2015 104 M
EBIT 2015 13,9 M
Net income 2015 11,3 M
Finance 2015 202 M
Yield 2015 -
Sales 2016 49,2 M
EBIT 2016 -20,9 M
Net income 2016 -34,2 M
Finance 2016 194 M
Yield 2016 -
P/E ratio 2015 79,15
P/E ratio 2016
EV / Sales 2015 7,13x
EV / Sales 2016 15,3x
Capitalization 946 M
More Financials
Company
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications.It operates through the following segments: Partnered Discovery, Proprietary Development and AbD Serotec.The Partnered Discovery segment involves technologies for the generation of human... 
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MORPHOSYS AG
01/29 MORPHOSYS : Announces Clinical Milestone for Start of Bayer's Phase 2 Trial Desi..
01/28 MORPHOSYS : Announces Clinical Milestone for Start of Bayer's Phase 2 Trial Desi..
01/26 MORPHOSYS : Announces Clinical Milestone for Start of Bayer's Phase 2 Trial Desi..
01/08 MORPHOSYS : to Present at J.P. Morgan Healthcare Conference
01/07 MORPHOSYS : to Present at J.P. Morgan Healthcare Conference
2015 MORPHOSYS : deploys Dotmatics' Vortex to Accelerate Antibody Research
2015 MORPHOSYS : New Clinical Data on MorphoSys's Blood Cancer Drug Candidate MOR208 ..
2015 MORPHOSYS : Presents Interim Safety, Pharmacokinetic and Efficacy Data for MOR20..
More news
Sector news : Biotechnology & Medical Research - NEC
05:04a PFIZER : Commends The FDA Advisory Committee's Vote To Approve Proposed Biosimil..
02/09DJPanel Recommends FDA Approval of Remicade Knockoff
02/09 JOHNSON & JOHNSON : FDA panel backs lower-cost version of J&J's top-selling drug
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2015 Sosei Springs Into Big Pharma's Arms With Heptares Acquisition
2015 MorphoSys' (MPSYF) CEO Simon Moroney on Q3 2015 Results - Earnings Call Trans..
2015 TOP 3 TRADE ALERT IDEAS SEPTEMBER 23 : Anavex Upside, Keryx's Potential, Amgen A..
2015 MorphoSys' (MPSYF) CEO Simon Moroney on Q2 2015 Results - Earnings Call Trans..
2015 MORPHOSYS : Dozens Of Partnerships And Self-Funded Growth


Comments 
Advertisement
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions